Infinity Pharmaceuticals, Inc.

NasdaqGS:INFI Stock Report

Mkt Cap: US$58.1m

Infinity Pharmaceuticals Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Adelene Perkins (62 yo)

13yrs

Tenure

US$1,149,287

Compensation

Ms. Adelene Q. Perkins has been the Chief Executive Officer of Infinity Pharmaceuticals, Inc. since January 2, 2010 and has been its Chairman since November 2012. Ms. Perkins served as the President of Inf...


CEO Compensation Analysis

How has Adelene Perkins's remuneration changed compared to Infinity Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$1mUS$690k

-US$45m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$3mUS$690k

-US$40m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$690k

-US$47m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$2mUS$690k

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$41m

Dec 31 2017US$3mUS$690k

-US$42m

Sep 30 2017n/an/a

-US$57m

Jun 30 2017n/an/a

-US$70m

Mar 31 2017n/an/a

US$88k

Dec 31 2016US$2mUS$669k

-US$30m

Compensation vs Market: Adelene's total compensation ($USD1.15M) is above average for companies of similar size in the US market ($USD727.78K).

Compensation vs Earnings: Adelene's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO13yrsUS$1.15m0.93%
$ 542.0k
Stephane Peluso
Chief Scientific Officer1.42yrsUS$1.32m0.041%
$ 24.1k
Robert Ilaria
Chief Medical Officer1.33yrsUS$1.52m0%
$ 0
Lawrence Bloch
President & Treasurer6yrsUS$1.81mno data
Melissa Hackel
Vice President of Finance6yrsno datano data
Seth Tasker
Senior VP6.5yrsUS$1.44mno data

6.0yrs

Average Tenure

56yo

Average Age

Experienced Management: INFI's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adelene Perkins
Chairman & CEO13yrsUS$1.15m0.93%
$ 542.0k
Anthony Evnin
Independent Director16.33yrsUS$140.47k0.24%
$ 140.0k
Norman Selby
Lead Independent Director10.83yrsUS$205.62k0.017%
$ 9.8k
David Beier
Independent Director4.75yrsUS$132.97k0.0098%
$ 5.7k
Roy Steven Herbst
Member of Scientific Advisory Board4.83yrsno datano data
Sujay Kango
Independent Director0.83yrUS$744.59k0%
$ 0
David Munn
Member of Scientific Advisory Board4.83yrsno datano data
F. Hodi
Member of Scientific Advisory Board4.83yrsno datano data
Richard B. Gaynor
Independent Director2.83yrsUS$140.97k0%
$ 0
Dmitry Gabrilovich
Member of Scientific Advisory Board4.83yrsno datano data
Jeffery Kutok
Chairman of Scientific Advisory Board2.83yrsUS$759.67kno data
Samuel Agresta
Chair of Clinical Advisory Board & Director3.25yrsUS$130.97k0.012%
$ 6.9k

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: INFI's board of directors are considered experienced (4.8 years average tenure).